modafinil has been researched along with Parkinson Disease in 13 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the therapeutic efficacy of modafinil in the treatment of increased daytime sleepiness in patients with Parkinson's disease (PD)." | 9.10 | Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. ( Brandauer, E; Frauscher, B; Glatzl, S; Högl, B; Poewe, W; Saletu, M; Seppi, K; Ulmer, H; Wenning, G, 2002) |
| "We assessed the safety and efficacy of modafinil for the treatment of excessive daytime sleepiness in patients with Parkinson's disease (PD)." | 9.10 | Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. ( Adler, CH; Caviness, JN; Hentz, JG; Lind, M; Tiede, J, 2003) |
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 8.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| "To assess the therapeutic efficacy of modafinil in the treatment of increased daytime sleepiness in patients with Parkinson's disease (PD)." | 5.10 | Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. ( Brandauer, E; Frauscher, B; Glatzl, S; Högl, B; Poewe, W; Saletu, M; Seppi, K; Ulmer, H; Wenning, G, 2002) |
| "We assessed the safety and efficacy of modafinil for the treatment of excessive daytime sleepiness in patients with Parkinson's disease (PD)." | 5.10 | Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. ( Adler, CH; Caviness, JN; Hentz, JG; Lind, M; Tiede, J, 2003) |
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 4.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| "Treatment with dopaminergic agents result excessive daytime sleepiness (EDS) and some studies have shown the benefit of using modafinil for treating excessive daytime sleepiness of Parkinson's disease (PD) patient." | 3.88 | Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease. ( Ando, R; Choudhury, ME; Kannou, M; Kubo, M; Kyaw, WT; Nagai, M; Nishikawa, N; Nomoto, M; Tanaka, J; Yamanishi, Y, 2018) |
| "Excessive daytime sleepiness (EDS) is a frequent and disabling symptom of Parkinson's disease (PD) without approved treatment." | 3.11 | THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. ( Azulay, JP; Bosse, B; Corvol, JC; Dauvilliers, Y; Defebvre, L; Klostermann, F; Kovacs, N; Maltête, D; Ondo, WG; Pahwa, R; Rascol, O; Rein, W; Thobois, S; Valis, M; Videnovic, A, 2022) |
| "Modafinil was titrated up over 4 weeks to maximum of 400 mg/day." | 2.75 | Modafinil for Parkinson's disease fatigue. ( Baker, GA; Steiger, MJ; Taylor, J; Tyne, HL, 2010) |
| "Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions." | 2.71 | Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. ( Atassi, F; Fayle, R; Jankovic, J; Ondo, WG, 2005) |
| "Excessive daytime sleepiness (EDS) is described as inappropriate and undesirable sleepiness during waking hours and is a common non-motor symptom in Parkinson's disease, affecting up to 50% of patients." | 2.47 | Excessive daytime sleepiness in patients with Parkinson's disease. ( Chaudhuri, KR; Knie, B; Logishetty, K; Mitra, MT, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Corvol, JC | 1 |
| Azulay, JP | 1 |
| Bosse, B | 1 |
| Dauvilliers, Y | 1 |
| Defebvre, L | 1 |
| Klostermann, F | 1 |
| Kovacs, N | 1 |
| Maltête, D | 1 |
| Ondo, WG | 2 |
| Pahwa, R | 1 |
| Rein, W | 1 |
| Thobois, S | 1 |
| Valis, M | 1 |
| Videnovic, A | 1 |
| Rascol, O | 1 |
| Folkerts, AK | 1 |
| Nielsen, J | 1 |
| Gollan, R | 1 |
| Lansu, A | 1 |
| Solfronk, D | 1 |
| Monsef, I | 1 |
| Ernst, M | 1 |
| Skoetz, N | 1 |
| Zeuner, KE | 1 |
| Kalbe, E | 1 |
| Ando, R | 1 |
| Choudhury, ME | 1 |
| Yamanishi, Y | 1 |
| Kyaw, WT | 1 |
| Kubo, M | 1 |
| Kannou, M | 1 |
| Nishikawa, N | 1 |
| Tanaka, J | 1 |
| Nomoto, M | 1 |
| Nagai, M | 1 |
| Fowler, E | 1 |
| Maderal, A | 1 |
| Yosipovitch, G | 1 |
| Garcia-Rill, E | 1 |
| Tyne, HL | 1 |
| Taylor, J | 1 |
| Baker, GA | 1 |
| Steiger, MJ | 1 |
| Knie, B | 1 |
| Mitra, MT | 1 |
| Logishetty, K | 1 |
| Chaudhuri, KR | 1 |
| Högl, B | 1 |
| Saletu, M | 1 |
| Brandauer, E | 1 |
| Glatzl, S | 1 |
| Frauscher, B | 1 |
| Seppi, K | 1 |
| Ulmer, H | 1 |
| Wenning, G | 1 |
| Poewe, W | 1 |
| Adler, CH | 1 |
| Caviness, JN | 1 |
| Hentz, JG | 1 |
| Lind, M | 1 |
| Tiede, J | 1 |
| Fayle, R | 1 |
| Atassi, F | 1 |
| Jankovic, J | 1 |
| Valentino, RM | 1 |
| Foldvary-Schaefer, N | 1 |
| Hauser, RA | 1 |
| Wahba, MN | 1 |
| Zesiewicz, TA | 1 |
| McDowell Anderson, W | 1 |
| Happe, S | 1 |
| Pirker, W | 1 |
| Sauter, C | 1 |
| Klösch, G | 1 |
| Zeitlhofer, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Bright Light Treatment on Daytime Sleepiness and Nocturnal Sleep in Patients With Parkinson's Disease[NCT01338649] | 27 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ESS score range is 0-24; lower ESS scores indicate less daytime sleepiness; higher ESS scores indicate more severe sleepiness ESS will be taken and compared at screening and week 4 visits between the bright light exposure and dim-red light exposure groups. (NCT01338649)
Timeframe: baseline and 4 weeks
| Intervention | score (Mean) |
|---|---|
| Bright White | 4.46 |
| Dim Red Light | 1.77 |
4 reviews available for modafinil and Parkinson Disease
| Article | Year |
|---|---|
Physical Exercise as a Potential Treatment for Fatigue in Parkinson's Disease? A Systematic Review and Meta-Analysis of Pharmacological and Non-Pharmacological Interventions.
Topics: Exercise; Humans; Modafinil; Parkinson Disease; Quality of Life | 2023 |
Neuroepigenetics of arousal: Gamma oscillations in the pedunculopontine nucleus.
Topics: Acetylation; Animals; Arousal; Calcium Channels; Central Nervous System Stimulants; Decerebrate Stat | 2019 |
Excessive daytime sleepiness in patients with Parkinson's disease.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Dopamine | 2011 |
Modafinil in the treatment of excessive daytime sleepiness.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2007 |
5 trials available for modafinil and Parkinson Disease
| Article | Year |
|---|---|
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
Topics: Disorders of Excessive Somnolence; Double-Blind Method; Drug Combinations; Flecainide; Humans; Modaf | 2022 |
Modafinil for Parkinson's disease fatigue.
Topics: Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Disability Evaluation; Dose-Response | 2010 |
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
Topics: Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Cross-Over Studies; Disorders of Exce | 2002 |
Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Cross-Over Studies; Disorders | 2003 |
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.
Topics: Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Do | 2005 |
4 other studies available for modafinil and Parkinson Disease
| Article | Year |
|---|---|
Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Arousal; Benzhydryl Compounds; Biogenic Monoamines; Disease Models, A | 2018 |
Treatment-induced Delusions of Infestation Associated with Increased Brain Dopamine Levels.
Topics: Aged; Attention Deficit Disorder with Hyperactivity; Brain; Deep Brain Stimulation; Delusional Paras | 2019 |
Modafinil treatment of pramipexole-associated somnolence.
Topics: Adult; Antiparkinson Agents; Benzhydryl Compounds; Benzothiazoles; Central Nervous System Stimulants | 2000 |
Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil.
Topics: Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Humans; Modafinil; Parkinson | 2001 |